NCT04686591 - Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 21, 2020

Primary Completion Date

February 4, 2021

Study Completion Date

February 4, 2021

Conditions

Cardiovascular Disease

Interventions

DRUG

AZD9977 capsule 50 mg

100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles)

DRUG

[14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)

One 100 µg dose of \[14C\]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)

DRUG

[14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)

One 100 mg dose of \[14C\]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)

Trial Locations (1)

Research Site, Ruddington